ClinicalTrials.gg
RecruitingNCT06577844SUVIDEMUpdated Nov 10, 2026

Evaluation of the Contribution of a DEMaterialized VIdeo-pedagogical SUpport in the Care Pathway of Lung Cancer Surgery Patients

An interventional study of video support in Lung Cancer, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.
Updated Nov 10, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 400 studies in Lung Neoplasms with a site in France — 114 open to participants now, 150 under way, 26 of them phase 3. Lung Neoplasms · France.

Planned enrollment
124th of 291
226 · median 170
Started
2024
with 30 others
No phase
110 of 400
32 open now
Primary completion
2028-01
later than 79 of 149 live
Registered
336th of 400
by date

Among the 400 studies in Lung Neoplasms with a site in France, this one is the 124th largest by planned enrollment of the 291 interventional ones that give a count, is one of 31 that started in 2024, is one of 110 with no phase, reaches primary completion later than 79 of the 149 other live ones, and was the 336th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

114 of the 400 studies in Lung Neoplasms with a site in France are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 400 studies in Lung Neoplasms with a site in France, or all of them as a file.
02

Study summary

Uni-centric, randomized, open-label, prospective interventional-comparative study, with a control arm (patients receiving standard preoperative information) and an experimental arm (patients receiving standard preoperative information and having access to a dematerialized educational video support).

03

Conditions studied

  • Lung Cancer

Keywords

  • lung cancer
  • surgery
  • anxiety
  • video support
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 or over,
  • Patients requiring surgical management:

for therapeutic purposes (in the case of proven tumor histology) or for diagnostic and therapeutic purposes (in the absence of proven histology, but strong suspicion, after validation by RCP),

- Patients who have given their consent.

Exclusion criteria

Exclusion Criteria:

  • Patients under guardianship
  • Patients with a history of thoracic surgery
  • Patients on long-term analgesic medication
  • Patients who do not speak French
  • Patients unable to read or write
  • Patients with major visual impairment
  • Patients with chronic anxiety or depression at the time of admission
  • Patients under guardianship
  • Pregnant or breast-feeding women
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
226 participants (estimated)

Study arms

  • Experimental
    experimental

    Other: video support

  • No intervention
    control

Interventions

  • Othervideo support

    video support provided to the patient before surgery

06

What researchers measure

Primary outcomes

  1. Immediate pre-operative anxiety

    self-measurement using the HAD Scale

    Time frame: 10 days

Secondary outcomes

  1. Perioperative anxiety (randomization (consultation), immediate postoperative and discharge)

    based on HAD scale

    Time frame: 90 days

  2. Post-traumatic stress disorder

    PCL-5 scale

    Time frame: 90 days

  3. Quality of life evaluation

    European Organisation for Research and Treatment of Cancer core health- related quality of life questionnaire (QLQ-C30).

    Time frame: 90 days

  4. Cumulative postoperative morbidity

    score CCI

    Time frame: 90 days

  5. Intra-hospital consumption of analgesics

    accounting for in-hospital consumption of analgesics

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jan 2028, 42 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 42 months is above that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jan 2026 → Jan 2028 and completion Apr 2026 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2024
First posted
Aug 29, 2024
StartActual
Jul 11, 2024
Primary completionEst.
Jan 11, 2028was Jan 2026
CompletionEst.
Apr 11, 2028was Apr 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Assistance publique Hopitaux de Marseille - Hopital Nord · Marseille, France
Show 1 removed
  • Assistance publique Hopitaux de Marseille - Hopital Nord · Marseille, France
Nov 10, 2026
Primary completion
Jan 11, 2026→Jan 11, 2028
Nov 10, 2026
Study completion
Apr 11, 2026→Apr 11, 2028
Nov 10, 2026
Contact
Study contact changed: p•••@ap-hm.fr · •••2747→a•••@ap-hm.fr · •••4395. See the current contact
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    1 site added, 1 site removed
    Show site
    • Assistance publique Hopitaux de Marseille - Hopital Nord · Marseille, France
    Show 1 removed
    • Assistance publique Hopitaux de Marseille - Hopital Nord · Marseille, France
    Primary completion Jan 11, 2026→Jan 11, 2028
    Study completion Apr 11, 2026→Apr 11, 2028
    Contact Study contact changed: p•••@ap-hm.fr · •••2747→a•••@ap-hm.fr · •••4395. See the current contact
    + 2 other changes: verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06577844
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Jul 11, 2024
Primary completion
Jan 11, 2028 (estimated)
Completion
Apr 11, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Alex FOURDRAIN, DR
Contact
alex.fourdrain@ap-hm.fr
+33 4 91 96 43 95

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion